Generative AI recommends. Physical AI acts.
That difference now sits at the center of healthcare and life sciences strategy. A new Harvard Business Review Analytic Services briefing paper in association with SoftServe, tracks how sensors, algorithms, and machines are starting to decide what happens in a lab, on a manufacturing line, and during a clinical procedure. If you lead this industry, you will recognize your next decision in it.
The shift is already underway
Life sciences automated in waves, and most waves stopped at tidy, repeatable tasks. Variable samples and changing experiments sent people back to the bench. The result was islands of automation instead of connected workflows.
Physical AI changes that. Paired with machine vision, simulation, and shared lab data, it perceives what's in front of it and adapts when conditions shift. Robot orders in life sciences, pharmaceutical, and biomedical sectors rose 32% during the first half of 2026 compared with the same period a year earlier. Treat that number as a signal that your peers are already testing where physical AI pays off.
The economics are moving, too, and the report reveals numbers on how far. SoftServe's view is that waiting now costs more than starting small.
Where the real constraint sits
The difficult part is reliability in places that change from minute to minute. Even the FDA says its evaluation methods were not designed to predict behavior in dynamic, real-world environments. That chasm explains why adoption clusters at the lab bench, the production line, and the imaging suite. Then, it slows as technology gets closer to the patient.
SoftServe sees closing that disparity as an engineering discipline, and it starts well before deployment. Validated performance, clear limits on autonomy, and monitoring that continues after launch decide whether a system earns trust or loses it. The experts in the report make the same case, and their reasoning is worth reading in full.
Autonomy with boundaries
The most credible deployments give machines freedom where they outperform people and keep human authority where judgment and accountability matter. The report calls this bounded autonomy and shows how cleanly the line can be drawn in a cardiac ultrasound workflow.
The payoff shows up as time. Every hour a scientist or clinician no longer spends on repetitive, variable work returns to the decisions only a person can make. SoftServe holds every use case to a high bar. The gain must be a step shift, unlike a marginal one, or it does not justify changing a clinical or biotech workflow.
Simulate before you commit
Digital twins let leaders find flawed assumptions before a system ever touches a patient or a valuable sample. The report describes a case where simulation stood in for a clinical trial and was held up. Simulation earns real weight in validation, provided controlled pilots and real-world testing follow.
That is why SoftServe starts with design and simulation and stays through deployment. We build embodied AI and intelligent systems that raise productivity and sharpen day-to-day operations, and we prove them before they meet a regulated floor.
What to do this quarter
Start where conventional automation is stalled. Inspection, liquid handling, and material movement combine repetitive work with enough variation to make fixed automation difficult to justify.
- Set the autonomy boundary and the point where the system hands off to a human before deployment begins.
- Budget for monitoring and changing control from the start.
- Build the first proof of concept, so it leaves something reusable behind, such as data infrastructure and validated components.
